LONDON (Alliance News) - Redx Pharma PLC Thursday said it has identified a new drug development candidate from its pipeline with a potential to treat cancers including pancreatic, triple negative breast, and head and neck cancers.
The candidate is the fourth to be advanced from its development pipeline in the last year, it said. Redx will now progress studies to prepare the compound for first-in-man clinical trials.
"We believe this compound has the potential to be a best-in-class therapy that can treat areas of high unmet need. Patients with difficult to treat cancers such as pancreatic, triple negative breast cancer and head and neck cancers could potentially achieve dramatically improved outcomes," said Chief Executive Officer Neil Murray in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
